ATS: Pulmonary Arterial Registry Risk Algorithms Improve Upon Clinical Trial Enrichment Methodology

Scott JV, Kanwar M, Garnett C, Stockbridge N, Benza RL. B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT: American Thoracic Society; 2020:A2920-A. Introduction: Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. Clinical trials for PAH now use time to morbidity/mortality event (clinical worsening) as the primary endpoint instead of six-minute walk distance (6MWD). These […]